Chronic obstructive pulmonary disease (COPD) results from an abnormal inflammatory response of the lungs to noxious particles or gases. Serum soluble urokinase-type plasminogen activator receptor (suPAR) is a glycoprotein secreted during infections and inflammation. The main goal of this study was to evaluate the serum suPAR level in stable COPD patients compared with a control group.
Methods
Forty-six stable COPD patients and 41 control subjects were included in the study. Blood samples were collected from 46 stable COPD patients (40 men, 6 women; mean [SD] age, 55.92 [7.91] years; the forced expiratory volume in 1 second, 45.32% [19.1%] of predicted). Forty-one healthy subjects were selected as control subjects and were matched to COPD patients with respect to age and body mass index. Serum suPAR and plasma fibrinogen levels were measured in stable COPD patients and control subjects.
Results
Serum suPAR levels of the COPD patients were significantly higher than those of the control subjects (4.94 [2.79] and 2.40 [2.01] ng/mL, respectively; P < 0.001). Plasma fibrinogen levels of the COPD patients were significantly higher than those of the control subjects (406.77 [172.6] and 336.53 [96.1] g/L, respectively; P < 0.05).
Conclusions
Our study indicated that serum suPAR may play an important role in the inflammatory process of COPD, and this increase may be particularly large for patients in Global Initiative for Chronic Obstructive Lung Disease stages III and IV. Serum suPAR and plasma fibrinogen level measurements may be useful for the evaluation of stable COPD.
ChungKF, AdcockIM.Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008; 31 (6): 1334–1356.
2.
AkpınarEE, AkpınarS, ErtekS, . Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks. 2012; 60 (3): 230–237.
3.
BarbuC, IordacheM, ManMG.Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011; 52 (1): 21–27.
4.
YaoH, RahmanI.Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol. 2011; 254 (2): 72–85.
5.
TkacovaR.Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm. 2010; 2010: 585989.
6.
DuvoixA, DickensJ, HaqI, . Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013; 68 (7): 670–676.
7.
OwenCA.Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3 (2): 253–268.
8.
FischerBM, PavliskoE, VoynowJA.Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011; 6: 413–421.
9.
AdcockIM, CaramoriG, BarnesPJ.Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011; 81 (4): 265–284.
10.
AnnaMS, WalshPT.Chronic obstructive pulmonary disease: evidence for an autoimmune component. Cell Mol Immunol. 2009; 6 (2): 81–86.
11.
BarnesPJ.The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008; 118 (11): 3546–3556.
12.
BeaufortN, LeducD, EguchiH, . The human airway trypsin-like protease modulates the urokinase receptor (uPAR, CD87) structure and functions. Am J Physiol Lung Cell Mol Physiol. 2007; 292 (5): L1263–L1272.
MizukamiIF, ToddRFIII.A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol. 1998; 64 (2): 203–213.
15.
ResnatiM, GuttingerM, ValcamonicaS, . Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996; 1; 15 (7): 1572–1582.
16.
StewartCE, SayersI.Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells. BMC Mol Biol. 2009; 28.
17.
BackesY, van der SluijsKF, MackieDP, . Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012; 38 (9): 1418–1428.
18.
SorioC, MafficiniA, FurlanF, . Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer. 2011; 11: 448.
19.
TaruiT, MazarAP, CinesDB, . Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem. 2001; 276 (6): 3983–3990.
20.
WeiC, El HindiS, LiJ, . Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17 (8): 952–960.
21.
DonadelloK, ScollettaS, CovajesC, . suPAR as a prognostic biomarker in sepsis. BMC Med. 2012; 10: 2.
22.
GustafssonA, AjetiV, LjunggrenL.Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomark Insights. 2011; 6: 119–125.
23.
PortelliMA, SiedlinskiM, StewartCE, . Genome mapping identifies human plasma kallikrein as a post translational regulator of serum uPAR levels. FASEB J. 2014; 28 (2): 923–934.
24.
LeaderD.The stages of COPD define the disease according to severity. AccessedSeptember13, 2012.
25.
BackesY, van der SluijsKF, Tuip de BoerAM, . Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care. 2011; 15 (6): R270.
26.
StewartCE, NijmehHS, BrightlingCE, . UPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. Thorax. 2012; 67 (6): 477–487.
27.
SlotO, BrünnerN, LochtH, . Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999; 58 (8): 488–492.
28.
KochA, VoigtS, KruschinskiC, . Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011; 15 (1): R63.
29.
WangQ, WangY, ZhangY, . The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2013; 28; 67.
30.
YehYH, WangPH, LinLY, . Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. Clin Chim Acta. 2013; 16; 415: 138–144.
31.
BartonSJ, KoppelmanGH, VonkJM, . PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol. 2009; 123 (6): 1391–1400.
32.
Mardining RarasTY, NoorCI. The soluble plasminogen activator receptor as a biomarker on monitoring the therapy progress of pulmonary TB-AFB(+) patients. Tuberc Res Treat. 2010: 406346.
33.
ShiX, LiH.Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med. 2013; 5 (5): 1367–1370.
34.
GanWQ, ManSF, SenthilselvanA, . Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574–580.
35.
DahlM, NordestgaardBG.Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis. 2009; 4: 157–167.
36.
ValviD, ManninoDM, MüllerovaH, . Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis. 2012; 7: 173–182.
